Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them. The study will compare how long patients live when they are given therapy to make them feel better (active symptom control) to the length of time patients live when they are also receiving oral HYCAMTIN.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Received one prior chemotherapy regimen only.
Documented partial or complete response to first-line therapy.
Documented relapse of limited or extensive SCLC at least 45 days after the cessation of first-line chemotherapy.
Not considered suitable for further intravenous chemotherapy.
Considered to have adequate bone marrow reserve.
Performance Status of 0, 1 or 2.
Pregnant or lactating.
Received more than one prior regimen of chemotherapy.
Active uncontrolled infection.
Received previous treatment with HYCAMTIN.
Received an investigational product within 30 days.